Related Experiment Video

Updated: Aug 19, 2026

Mechanical Control of Relaxation Using Intact Cardiac Trabeculae
07:51

Mechanical Control of Relaxation Using Intact Cardiac Trabeculae

Published on: February 17, 2023

Putting the brakes on cardiac hypertrophy: exploiting the NO-cGMP counter-regulatory system

George W Booz1

  • 1Cardiovascular Research Institute, the Texas A&M University System Health Science Center, College of Medicine, Temple, Tex, USA. gbooz@medicine.tamhsc.edu

Hypertension (Dallas, Tex. : 1979)
|February 16, 2005
PubMed

Insights

Naturally occurring regulators, like the nitric oxide-cyclic guanosine monophosphate (NO-cGMP) system, offer new therapeutic strategies for cardiac hypertrophy. Research highlights these endogenous molecules

Area of Science:

  • Cardiovascular Physiology
  • Molecular Cardiology
  • Pharmacology

Background:

  • Existing drugs targeting cardiomyocyte signaling pathways reduce left ventricular hypertrophy but cardiovascular disease remains a leading cause of death.
  • Naturally occurring negative regulators of cardiac hypertrophy have been identified, offering alternative therapeutic avenues.
  • These regulators are either constitutively active with decreased activity under stimulation or activated by stimulation.

Purpose of the Study:

  • To review recent research (past 2 years) on endogenous signaling molecules that restrict maladaptive cardiac hypertrophy.
  • To focus on four systems converging on cyclic guanosine 3', 5'-monophosphate (cGMP) generation: natriuretic peptides, kinins, nitric oxide (NO), and the angiotensin II type 2 receptor (AT2).
  • To explore the potential of the antihypertrophic nitric oxide-cyclic guanosine monophosphate (NO-cGMP) system for novel therapeutic strategies.

Main Methods:

  • Review of scientific literature published within the last two years, with a focus on studies in Hypertension.
  • Analysis of endogenous negative regulators of cardiac hypertrophy.
  • Examination of signaling pathways converging on cGMP generation.

Main Results:

  • Identified endogenous negative regulators of cardiac hypertrophy, categorized by their activity patterns.
  • Highlighted four key signaling systems (natriuretic peptides, kinins, NO, AT2 receptor) that converge on cGMP generation.
  • Acknowledged limitations associated with current therapeutic applications of these signaling molecules.

Conclusions:

  • The NO-cGMP system, as an antihypertrophic regulator, presents promising therapeutic potential for cardiac hypertrophy and heart failure.
  • Further understanding of the function and regulation of the NO-cGMP system is crucial for developing novel treatments.
  • Exploiting endogenous regulators offers a complementary approach to existing drug therapies for cardiovascular diseases.

More Related Videos

Magnetic Adjustment of Afterload in Engineered Heart Tissues09:40

Magnetic Adjustment of Afterload in Engineered Heart Tissues

Published on: May 5, 2020

Technique of Minimally Invasive Transverse Aortic Constriction in Mice for Induction of Left Ventricular Hypertrophy08:34

Technique of Minimally Invasive Transverse Aortic Constriction in Mice for Induction of Left Ventricular Hypertrophy

Published on: September 25, 2017

Related Concept Videos

G-Protein Gated Ion Channels01:21

G-Protein Gated Ion Channels

GPCRs are primarily responsible for our sense of smell, taste, and vision.  The binding of a sensory stimulus activates GPCR to stimulate effector proteins, many of which are ion channels in the sensory organs. GPCRs modulate the opening and closing of the target ion channels either directly by binding them, or by releasing second messengers that activate these channels. As ions move across the membrane, the membrane potential is altered, which induces an appropriate response.
Sensory organs,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of cells.
Two...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...